Peptide codes for organ-selective mRNA delivery
Source abstract
Abstract
Organ-selective delivery of messenger RNA (mRNA) is critical for fulfilling the therapeutic potential of mRNA-based gene and protein replacement technologies. Despite clinical advances in the hepatic delivery of mRNA using lipid nanoparticles (LNPs), current strategies for extrahepatic-organ-selective mRNA delivery still have limitations. Here we report a peptide-encoded organ-selective targeting (POST) method for the delivery of mRNA to extrahepatic organs after systemic administration, which is based on the modular tuning of LNPs through surface engineering with specific amino acid sequences (POST codes). Molecular dynamics simulations and in vitro and in vivo testing show that the organ-selective targeting of POST results from the specific protein corona of the peptide-decorated LNPs, which is established from the mechanical optimization of the binding affinities between peptides with a particular sequence and plasma proteins. This approach can be used for the organ-selective delivery of different ribonucleic acids and multiple gene editing machinery. Overall, the POST platform creates a modular repertoire for LNP surface engineering for directing organ tropism, broadening the scope and versatility of organ-selective delivery.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (79)
Show source-provided references
1. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).10.1038/s41587-022-01294-2 ↗
2. Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).10.1038/s41587-019-0247-3 ↗
3. Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).10.1038/s41568-023-00586-2 ↗
4. Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).10.1038/s41587-022-01491-z ↗
5. Chabanovska, O., Galow, A. M., David, R. & Lemcke, H. mRNA—a game changer in regenerative medicine, cell-based therapy and reprogramming strategies. Adv. Drug Deliv. Rev. 179, 114002 (2021).10.1016/j.addr.2021.114002 ↗
6. Hou, X. C., Zaks, T., Langer, R. & Dong, Y. Z. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 7, 65–65 (2022).10.1038/s41578-021-00400-1 ↗
7. Huang, X. G. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17, 1027–1037 (2022).10.1038/s41565-022-01174-5 ↗
8. Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084–1087 (2019).10.1038/s41565-019-0591-y ↗
9. Dahlman, J. E. & Loughrey, D. Non-liver mRNA delivery. Acc. Chem. Res. 55, 13–23 (2022).10.1021/acs.accounts.1c00601 ↗
10. Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282–300 (2023).10.1038/s41578-022-00529-7 ↗
11. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313–316 (2020).10.1038/s41565-020-0669-6 ↗
12. Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 119, e2116271119 (2022).10.1073/pnas.2116271119 ↗
13. Riley, R. S. et al. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci. Adv. 7, eaba10 (2021).10.1126/sciadv.aba1028 ↗
14. Mitchell, M. J. et al. Ionizable lipid nanoparticles for in vivo mRNA Delivery to the placenta during pregnancy. J. Am. Chem. Soc. 145, 4691–4706 (2023).10.1021/jacs.2c12893 ↗
15. Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
16. Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).10.1073/pnas.2109256118 ↗
17. Poon, W., Kingston, B. R., Ouyang, B., Ngo, W. & Chan, W. C. W. A framework for designing delivery systems. Nat. Nanotechnol. 15, 819–829 (2020).10.1038/s41565-020-0759-5 ↗
18. Kedmi, R. et al. A modular platform for targeted RNAi therapeutics. Nat. Nanotechnol. 13, 214–219 (2018).10.1038/s41565-017-0043-5 ↗
19. Levin, A. et al. Biomimetic peptide self-assembly for functional materials. Nat. Rev. Chem. 4, 615–634 (2020).10.1038/s41570-020-0215-y ↗
20. Huang, J. J. et al. Identification of potent antimicrobial peptides via a machine-learning pipeline that mines the entire space of peptide sequences. Nat. Biomed. Eng. 7, 797–810 (2023).10.1038/s41551-022-00991-2 ↗
21. Xie, J. et al. Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front. Pharmacol. 11, 697 (2020).10.3389/fphar.2020.00697 ↗
22. Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122–128 (2015).10.1016/j.drudis.2014.10.003 ↗
23. Foss, D. V. et al. Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nat. Biomed. Eng. 7, 647–660 (2023).10.1038/s41551-023-01032-2 ↗
24. Zhang, Z. et al. Efficient engineering of human and mouse primary cells using peptide-assisted genome editing. Nat. Biotechnol. 42, 305–315 (2023).10.1038/s41587-023-01756-1 ↗
25. Rhym, L. H., Manan, R. S., Koller, A., Stephanie, G. & Anderson, D. G. Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery. Nat. Biomed. Eng. 7, 901–910 (2023).10.1038/s41551-023-01030-4 ↗
26. Rossler, S. L., Grob, N. M., Buchwald, S. L. & Pentelute, B. L. Abiotic peptides as carriers of information for the encoding of small-molecule library synthesis. Science 379, eadf1354 (2023).10.1126/science.adf1354 ↗
27. Huang, W. M. et al. Maleimide-thiol adducts stabilized through stretching. Nat. Chem. 11, 310–319 (2019).10.1038/s41557-018-0209-2 ↗
28. Stroock, A. et al. Chaotic mixer for microchannels. Science 295, 647–651 (2002).10.1126/science.1066238 ↗
29. Li, S. D. & Huang, L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release 145, 178–181 (2010).10.1016/j.jconrel.2010.03.016 ↗
30. Wang, S. et al. The role of protein corona on nanodrugs for organ-targeting and its prospects of application. J. Control. Release 360, 15–43 (2023).10.1016/j.jconrel.2023.06.014 ↗
31. Oh, J. Y. et al. Cloaking nanoparticles with protein corona shield for targeted drug delivery. Nat. Commun. 9, 4548 (2018).10.1038/s41467-018-06979-4 ↗
32. Bashiri, G. et al. Nanoparticle protein corona: from structure and function to therapeutic targeting. Lab Chip 23, 1432–1466 (2023).10.1039/D2LC00799A ↗
33. Ngo, W. et al. Identifying cell receptors for the nanoparticle protein corona using genome screens. Nat. Chem. Biol. 18, 1023–1031 (2022).10.1038/s41589-022-01093-5 ↗
34. Singh, B., Fu, C. & Bhattacharya, J. Vascular expression of the αvβ3-integrin in lung and other organs. Am. J. Physiol. Lung Cell. Mol. Physiol. 278, L217–L226 (2000).10.1152/ajplung.2000.278.1.L217 ↗
35. Teoh, C., Tan, S. & Tran, T. Integrins as therapeutic targets for respiratory diseases. Curr. Mol. Med. 15, 714–734 (2015).10.2174/1566524015666150921105339 ↗
36. Shanker, V. R., Bruun, T. U. J., Hie, B. L. & Kim, P. S. Unsupervised evolution of protein and antibody complexes with a structure-informed language model. Science 385, 46–53 (2024).10.1126/science.adk8946 ↗
37. Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500 (2024).10.1038/s41586-024-07487-w ↗
38. Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).10.1016/j.ijpharm.2021.120586 ↗
39. Huang, X. G. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273–2287 (2022).10.1038/s41591-022-02061-1 ↗
40. Zhang, Y. B., Sun, C. Z., Wang, C., Jankovic, K. E. & Dong, Y. Z. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181–12277 (2021).10.1021/acs.chemrev.1c00244 ↗
41. Hajj, K. A. et al. A potent branched-tail lipid nanoparticle enables multiplexed mRNA delivery and gene editing in vivo. Nano Lett. 20, 5167–5175 (2020).10.1021/acs.nanolett.0c00596 ↗
42. Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673–694 (2020).10.1038/s41573-020-0075-7 ↗
43. Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022).10.1038/s41576-021-00439-4 ↗
44. Yang, L. et al. Efficient delivery of antisense oligonucleotides using bioreducible lipid nanoparticles in vitro and in vivo. Mol. Ther. Nucleic Acids 19, 1357–1367 (2020).10.1016/j.omtn.2020.01.018 ↗
45. Liang, X. H. et al. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat. Biotechnol. 34, 875–880 (2016).10.1038/nbt.3589 ↗
46. Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E. & Dow, L. E. CRISPR in cancer biology and therapy. Nat. Rev. Cancer 22, 259–279 (2022).10.1038/s41568-022-00441-w ↗
47. Platt, R. J. et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455 (2014).10.1016/j.cell.2014.09.014 ↗
48. Kim, G. B. et al. Rapid generation of somatic mouse mosaics with locus-specific, stably integrated transgenic elements. Cell 179, 251–267 (2019).10.1016/j.cell.2019.08.013 ↗
49. Finn, J. D. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227–2235 (2018).10.1016/j.celrep.2018.02.014 ↗
50. Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73–80 (2015).10.1038/nbt.3081 ↗
51. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003).10.1016/S1535-6108(03)00215-0 ↗
52. Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949–957 (2021).10.1038/s41587-021-00933-4 ↗
53. Donati, Y., Blaskovic, S., Ruchonnet-Métrailler, I., Lascano Maillard, J. & Barazzone-Argiroffo, C. Simultaneous isolation of endothelial and alveolar epithelial type I and type II cells during mouse lung development in the absence of a transgenic reporter. Am. J. Physiol. Lung Cell. Mol. Physiol. 318, L619–L630 (2020).10.1152/ajplung.00227.2019 ↗
54. Toulmin, S. A. et al. Type II alveolar cell MHCII improves respiratory viral disease outcomes while exhibiting limited antigen presentation. Nat. Commun. 12, 3993 (2021).10.1038/s41467-021-23619-6 ↗
55. Olesch, C. et al. Picturing of the lung tumor cellular composition by multispectral flow cytometry. Front. Immunol. 13, 827719 (2022).10.3389/fimmu.2022.827719 ↗
56. Sun, Y. et al. In vivo editing of lung stem cells for durable gene correction in mice. Science 384, 1196–1202 (2024).10.1126/science.adk9428 ↗
57. Modulation of CD19 surface expression in B cell acute lymphoblastic leukemia. Nat. Immunol. 23, 1410–1411 (2022).10.1038/s41590-022-01316-w ↗
58. Swingle, K. L. et al. Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia. Nature https://doi.org/10.1038/s41586-024-08291-2 (2024).10.1038/s41586-024-08291-2 ↗
59. Lian, X. et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat. Nanotechnol. 19, 1409–1417 (2024).10.1038/s41565-024-01680-8 ↗
60. Adolfsson, J. et al. Upregulation of Flt3 expression within the bone marrow Lin−Sca1+c-kit+ stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 15, 659–669 (2001).10.1016/S1074-7613(01)00220-5 ↗
61. Engelhard, S. et al. Endomucin marks quiescent long-term multi-lineage repopulating hematopoietic stem cells and is essential for their transendothelial migration. Cell Rep. 43, 114475 (2024).10.1016/j.celrep.2024.114475 ↗
62. Mayle, A., Luo, M., Jeong, M. & Goodell, M. A. Flow cytometry analysis of murine hematopoietic stem cells. Cytom. Part A 83A, 27–37 (2013).10.1002/cyto.a.22093 ↗
63. Rodeheffer, M. S., Birsoy, K. & Friedman, J. M. Identification of white adipocyte progenitor cells in vivo. Cell 135, 240–249 (2008).10.1016/j.cell.2008.09.036 ↗
64. Lee, Y.-H., Petkova, A. P., Mottillo, E. P. & Granneman, J. G. In vivo identification of bipotential adipocyte progenitors recruited by β3-adrenoceptor activation and high-fat feeding. Cell Metab. 15, 480–491 (2012).10.1016/j.cmet.2012.03.009 ↗
65. Garritson, J. D. et al. BMPER is a marker of adipose progenitors and adipocytes and a positive modulator of adipogenesis. Commun. Biol. 6, 638 (2023).10.1038/s42003-023-05011-w ↗
66. Zomer, H. D. & Reddi, P. P. Characterization of rodent Sertoli cell primary cultures. Mol. Reprod. Dev. 87, 857–870 (2020).10.1002/mrd.23402 ↗
67. Song, Y., Zhang, X., Desmarais, J. A. & Nagano, M. Postnatal development of mouse spermatogonial stem cells as determined by immunophenotype, regenerative capacity, and long-term culture-initiating ability: a model for practical applications. Sci. Rep. 14, 2299 (2024).10.1038/s41598-024-52824-8 ↗
68. Omo-Lamai, S. et al. Physicochemical targeting of lipid nanoparticles to the lungs induces clotting: mechanisms and solutions. Adv. Mater. 36, 2312026 (2023).10.1002/adma.202312026 ↗
69. Witten, J. et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02490-y (2024).10.1038/s41587-024-02490-y ↗
70. Li, B. et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat. Mater. 23, 1002–1008 (2024).10.1038/s41563-024-01867-3 ↗
71. Dobrowolski, C. et al. Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery. Nat. Nanotechnol. 17, 871–879 (2022).10.1038/s41565-022-01146-9 ↗
72. Phillips, J. C. et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J. Chem. Phys. 153, 044130 (2020).10.1063/5.0014475 ↗
73. Best, R. B. et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain χ1 and χ2 dihedral angles. J. Chem. Theory Comput. 8, 3257–3273 (2012).10.1021/ct300400x ↗
74. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926–935 (1983).10.1063/1.445869 ↗
75. Sali, A. & Blundell, T. L. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993).10.1006/jmbi.1993.1626 ↗
76. Abdin, O., Nim, S., Wen, H. & Kim, P. M. PepNN: a deep attention model for the identification of peptide binding sites. Commun. Biol. 5, 503 (2022).10.1038/s42003-022-03445-2 ↗
77. Kozlovskii, I. & Popov, P. Protein-peptide binding site detection using 3D convolutional neural networks. J. Chem. Inf. Model. 61, 3814–3823 (2021).10.1021/acs.jcim.1c00475 ↗
78. Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A. & Moreno, E. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 17, 6281–6291 (2021).10.1021/acs.jctc.1c00645 ↗
79. Miller, B. R. III et al. MMPBSA.py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314–3321 (2012).10.1021/ct300418h ↗